Actelion re-enters transaction talks with Johnson & Johnson
Frankfurt
SWISS biotech company Actelion has turned back to prospective bidder Johnson & Johnson (J&J) for exclusive talks about a "strategic transaction", in an about-turn that appears to sideline rival suitor Sanofi.
Actelion said in a brief statement on Wednesday that it was in exclusive negotiations with the US health care giant but that there could be "no assurance any transaction will result from these discussions", declining to comment further.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
IndoAgri appoints former EDB chairman Philip Yeo as chairman and lead ID
GSK profit drops in first quarter on higher costs
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices